Global Partners LP ( GLP ) Nowojorska Giełda Papierów Wartościowych

Cena: 54.0 ( -1.85% )

Aktualizacja 06-20 22:00
Nowojorska Giełda Papierów Wartościowych
Branża: Oil & Gas Midstream
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Energetyka
Branża: Oil & Gas Midstream
Zatrudnienie: 3 485
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 85%
Ilość akcji: 33 995 600
Debiut giełdowy: 2005-09-29
WWW: https://www.globalp.com
CEO: Mr. Eric S. Slifka
Adres: 800 South Street
Siedziba: 02454-9161 Waltham
ISIN: US37946R1095
Opis firmy:

Global Partners LP angażuje się w zakupy, sprzedaż, gromadzenie, mieszanie, przechowywanie i logistykę transportu mieszanek benzyny i benzyny, destylatów, resztkowych ropy, paliw odnawialnych, ropy naftowej i propanu do hurtowników, detalicznych i klientów komercyjnych w stanach Nowej Anglii, regionie średniego atlantyckiego. Firma bierze również udział w transporcie produktów ropopochodnych i paliw odnawialnych przez kolei z regionu Środkowego Contynentu w Stanach Zjednoczonych i Kanadzie. Jego hurtowy segment sprzedaje domowe olej ogrzewania, markową i niezaprzeczoną mieszanki benzyny i benzyny, olej napędowy, nafty, resztkowy olej i propan do domowych sprzedawców oleju i dystrybutorów hurtowych. Agreguje także ropę naftową przez ciężarówkę lub rurociąg w regionie Środkowym Content w Stanach Zjednoczonych i Kanadzie, a także przenosi ją przez szynę i wysyła ją przez barkę do rafinerów. Segment dystrybucji benzyny i działalności benzynowej firmy sprzedaje markowe i niezaprzeczoną benzynę operatorom stacji benzynowej i podmiotom podrzędnym; obsługuje stacje benzynowe i sklepy spożywcze; i zapewnia usługi myjni samochodowej, loterii i bankomatów, a także dzierżawie stacje benzynowe. Jego segment komercyjny sprzedaje i dostarcza niezaprzeczoną benzynę, domową olej grzewczy, olej napędowy, naftę, resztkową olej i paliwo bunkra dla klientów w sektorze publicznym, a także komercyjnym i przemysłowym użytkownikom końcowym; i sprzedaje niestandardowe mieszane paliwa. Na dzień 31 grudnia 2021 r. Spółka miała portfel o wartości 1595 osób, wynajętych i dostarczanych stacji benzynowych, w tym 295 bezpośrednio obsługiwanych sklepów spożywczych; oraz posiadane, dzierżawione lub utrzymywane urządzenia do przechowywania w 26 terminach masowych o zbiorowej pojemności 11,9 miliona baryłek. Global GP LLC pełni funkcję komplementariusza firmy. Firma została zarejestrowana w 2005 roku i ma siedzibę w Waltham, Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 1 835 762 400
Aktywa: 3 665 115 000
Cena: 54.0
Wskaźnik Altman Z-Score: 6.6
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 3
P/E: 17.2
Ilość akcji w obrocie: 85%
Średni wolumen: 55 972
Ilość akcji 33 995 600
Wskaźniki finansowe
Przychody TTM 21 522 629 000
Zobowiązania: 2 941 793 000
Przedział 52 tyg.: 37.0 - 60.0
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: 3.1
P/E branży: 12.8
Beta: 1.371
Raport okresowy: 2025-08-05
WWW: https://www.globalp.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Eric S. Slifka President, Chief Executive Officer & Vice Chairman of Global GP LLC 9 081 871 1966
Mr. Mark A. Romaine Chief Operating Officer of Global GP LLC 3 869 433 1969
Mr. Gregory B. Hanson Chief Financial Officer of Global GP LLC 2 193 159 1978
Mr. Sean T. Geary Chief Legal Officer & Secretary 1 716 286 1968
Mr. Matthew Spencer Chief Accounting Officer of Global GP LLC 1 579 040 1979
Mr. Scott Solomon Vice President of Investor Relations 0 0
Ms. Maura McDonough Chief People Officer 0 0
Lorraine Spadaro Chief Information Officer 0 0
Catie Kerns Vice President of Communications & SVP of Corporate Affairs 0 0
Philip Segaloff Senior Associate General Counsel 0 0
Wiadomości dla Global Partners LP
Tytuł Treść Źródło Aktualizacja Link
Cramer's Mad Dash: Cornell report on GLP-1s shows decrease in consumption of savory snacks CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market. youtube.com 2025-01-03 13:19:29 Czytaj oryginał (ang.)
Should You Buy the Dip in Novo Nordisk Stock Right Now? The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chronic weight management, although research suggests these medications could have other applications in areas such as sleep apnea, kidney disease, and cardiovascular complications. fool.com 2025-01-02 10:30:00 Czytaj oryginał (ang.)
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. "This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. youtube.com 2024-12-29 11:00:09 Czytaj oryginał (ang.)
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals. barrons.com 2024-12-19 18:21:00 Czytaj oryginał (ang.)
Viking Therapeutics: Holiday Gift Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment. seekingalpha.com 2024-12-19 12:30:00 Czytaj oryginał (ang.)
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha (TNF-α) inhibitor drug isomyosamine (MYMD-1) as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded study is expected to evaluate. businesswire.com 2024-12-19 11:15:00 Czytaj oryginał (ang.)
Lexaria's Registered GLP-1 Study #4 Begins Dosing Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs. accesswire.com 2024-12-19 11:05:00 Czytaj oryginał (ang.)
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Compan. businesswire.com 2024-12-19 10:30:00 Czytaj oryginał (ang.)
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. marketbeat.com 2024-12-18 12:38:08 Czytaj oryginał (ang.)
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial) BEIJING and BRIDGEWATER, N.J. , Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct a phase 2 clinical trial, a head-to-head with Tirzepatide from Eli Lilly and Company (NYSE: LLY) in the US (NCT06737042). prnewswire.com 2024-12-18 08:01:00 Czytaj oryginał (ang.)
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and short-term subjects, completes a critical phase of the study. accesswire.com 2024-12-16 10:50:00 Czytaj oryginał (ang.)
Conagra Brands Introduces Badges on Select Healthy Choice Products, Leading Consumers to GLP-1-Friendly Options CHICAGO , Dec. 12, 2024 /PRNewswire/ -- With the rising popularity of GLP-1 medications among Americans for diabetes and weight management, Conagra Brands is proud to announce a first-of-its-kind initiative in the food industry. Starting in January 2025, the company's Healthy Choice® line will feature an "On Track" badge on 26 select items, indicating that the products are high in protein, low calorie, and a good source of fiber, which make these items "GLP-1 friendly. prnewswire.com 2024-12-12 12:28:00 Czytaj oryginał (ang.)
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of a contract research organization ("CRO") to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda® injectable liraglutide. As reported on November 20th in Lexaria's 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide - administered orally - demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline. accesswire.com 2024-12-09 11:10:00 Czytaj oryginał (ang.)
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place December 12-14, 2024. globenewswire.com 2024-12-09 09:00:00 Czytaj oryginał (ang.)
Structure CEO on the competitive landscape for oral GLP-1 drugs Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings. youtube.com 2024-12-05 20:17:59 Czytaj oryginał (ang.)
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and exclusion criteria t. businesswire.com 2024-12-04 09:30:00 Czytaj oryginał (ang.)
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now? There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized healthcare company. fool.com 2024-12-03 10:27:00 Czytaj oryginał (ang.)
Fmr. FDA Commissioner on how Trump could impact GLP-1 industry Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry. youtube.com 2024-12-02 20:03:18 Czytaj oryginał (ang.)
Millions more Americans might get access to GLP-1 drugs A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as investors tried to pick winners and losers in Donald Trump's tariff plans. youtube.com 2024-11-26 18:21:59 Czytaj oryginał (ang.)
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid. youtube.com 2024-11-26 13:33:02 Czytaj oryginał (ang.)